Description
Zaltrap 200mg 8ml is a sterile, clear, colorless to pale yellow, non-pyrogenic, preservative-free, solution for administration by intravenous infusion.
ZALTRAP is available as:
100 mg per 4 mL (25 mg per mL) solution, single-use vial
200 mg per 8 mL (25 mg per mL) solution, single-use vial
Zaltrap is the first fruit of Sanofi’s open-innovation R&D strategy which has gained reimbursement after winning domestic approval four years ago,” said Sanofi Genzyme CEO Park Hee-kyung. “Making total solution care for metastatic rectal cancer possible will contribute to the long-term survival rate of Korean patients and resolve the unmet demand for existing treatments.”
The VELOUR clinical trial showed Zaltrap (ingredient: aflibercept) in combination with Folfiri proved statistical significance in all aspects of overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to patients receiving a placebo-Folfiri combination, the company said. The trial involved 1,226 patients, including around 60 Korean patients with metastatic colorectal cancer.
Zaltrap 200mg 8ml
It pitted a Zaltrap-Folfiri combination against a placebo-Folfiri combination, finding the Zaltrap arm had a median OS rate of 13.5 months versus 12.06 in the placebo group, cutting the risk of death by 18 percent. PFS was also longer in the combination arm at 6.9 months compared to 4.67 months in the placebo group. ORR was also significant, 19.8 percent versus 11.1 percent.
Zaltrap is the first fruit of Sanofi’s open-innovation R&D strategy which has gained reimbursement after winning domestic approval four years ago,” said Sanofi Genzyme CEO Park Hee-kyung. “Making total solution care for metastatic rectal cancer possible will contribute to the long-term survival rate of Korean patients and resolve the unmet demand for existing treatments.”
The VELOUR clinical trial showed Zaltrap (ingredient: aflibercept) in combination with Folfiri proved statistical significance in all aspects of overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to patients receiving a placebo-Folfiri combination, the company said. The trial involved 1,226 patients, including around 60 Korean patients with metastatic colorectal cancer.
Zaltrap 200mg 8ml
Reviews
There are no reviews yet.